HepaTx

HepaTx is developing regenerative medicine solutions to meet the demand for better therapies for life-threatening liver diseases. The technology invented by Stanford University can efficiently produce hepatocytes for therapeutic purposes. Its treatment can replace lost liver function to treat patients with end-stage liver disease, potentially saving the costs and morbidity associated with whole-organ transplantation. HepaTx was founded in 2015 and is headquartered in Palo Alto, California.